Literature DB >> 19144813

Role of SCCmec type in outcome of Staphylococcus aureus bacteremia in a single medical center.

Roopa Ganga1, Kathleen Riederer, Mamta Sharma, Mohamad G Fakih, Leonard B Johnson, Stephen Shemes, Riad Khatib.   

Abstract

Staphylococcus aureus virulence factors may determine infection presentation. Whether SCCmec type-associated factors play a role in S. aureus bacteremia is unclear. We conducted a prospective observation of adult inpatients with S. aureus bacteremia (1 November 2005 to 31 December 2006), performed SCCmec typing of methicillin-resistant S. aureus (MRSA) isolates, and stratified the results according to SCCmec type. We studied 253 patients. MRSA accounted for 163 (64.4%) cases. The illness severity index was similar in MRSA and methicillin-sensitive S. aureus (MSSA) cases. MRSA caused higher in-hospital mortality (23.9% versus 8.9%; P=0.003), longer bacteremia (4.7+/-6.5 days versus 2.7+/-2.9 days; P=0.01), but similar metastatic infection (14.7% versus 15.6%). Stratifying the results according to SCCmec type revealed significant differences. SCCmec type II caused highest mortality (33.3%) versus type IVa (13.5%), other MRSA (12.5%), and MSSA (8.9%). SCCmec IVa produced the highest metastatic infection (26.9% versus 9.1% [SCCmec II], 8.3% [other MRSA], and 15.6% [MSSA]). Persistent bacteremia (>or= 7 days) was similar in all SCCmec types (16.7 to 20.7%); each exceeded MSSA (6.7%; P=0.05). In multivariate analysis, SCCmec II was a predictor of mortality (odds ratio [OR]=3.73; 95% confidence interval [CI] = 1.81 to 7.66; P=0.009), SCCmec IVa was a predictor of metastatic infection (OR=3.52; CI=1.50 to 8.23; P=0.004), and MRSA (independent of SCCmec type) was a predictor of persistent bacteremia (OR=4.16; CI=1.47 to 11.73; P=0.007). These findings suggest that SCCmec-associated virulence factors play a role in the outcome of S. aureus bacteremia. Additional studies are needed to identify which virulence factors are the determinants of increased mortality with SCCmec type II and metastatic infection with SCCmec type IVa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144813      PMCID: PMC2650895          DOI: 10.1128/JCM.00397-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.

Authors:  A Soriano; J A Martínez; J Mensa; F Marco; M Almela; A Moreno-Martínez; F Sánchez; I Muñoz; M T Jiménez de Anta; E Soriano
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

2.  Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci.

Authors:  Sung-Han Kim; Wan-Bum Park; Ki-Deok Lee; Cheol-In Kang; Hong-Bin Kim; Myoung-don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

3.  Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection.

Authors:  Vance G Fowler; Charlotte L Nelson; Lauren M McIntyre; Barry N Kreiswirth; Alastair Monk; Gordon L Archer; Jerome Federspiel; Steven Naidich; Brian Remortel; Thomas Rude; Pamela Brown; L Barth Reller; G Ralph Corey; Steven R Gill
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

4.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease.

Authors:  Sophie Jarraud; Christophe Mougel; Jean Thioulouse; Gerard Lina; Hélène Meugnier; Françoise Forey; Xavier Nesme; Jerome Etienne; François Vandenesch
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

7.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

8.  Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein.

Authors:  Vance G Fowler; George Sakoulas; Lauren M McIntyre; Venkata G Meka; Robert D Arbeit; Christopher H Cabell; Martin E Stryjewski; George M Eliopoulos; L Barth Reller; G Ralph Corey; Tiffanny Jones; Natalie Lucindo; Michael R Yeaman; Arnold S Bayer
Journal:  J Infect Dis       Date:  2004-08-12       Impact factor: 5.226

9.  Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus.

Authors:  Sharon J Peacock; Catrin E Moore; Anita Justice; Maria Kantzanou; Lisa Story; Kathryn Mackie; Gael O'Neill; Nicholas P J Day
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.

Authors:  Farid M Hussain; Susan Boyle-Vavra; Priya B Shete; Robert S Daum
Journal:  J Infect Dis       Date:  2002-08-01       Impact factor: 5.226

View more
  22 in total

1.  Clinical outcomes by methicillin-resistant Staphylococcus aureus staphylococcal cassette chromosome mec type: isolates recovered from a phase IV clinical trial of linezolid and vancomycin for complicated skin and skin structure infections.

Authors:  David B Huang; Arlene Reisman; Patricia Hogan
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 2.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

3.  Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.

Authors:  Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

4.  agr dysfunction affects staphylococcal cassette chromosome mec type-dependent clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Chang Kyung Kang; Jeong Eun Cho; Yoon Jeong Choi; Younghee Jung; Nak-Hyun Kim; Chung-Jong Kim; Taek Soo Kim; Kyoung-Ho Song; Pyoeng Gyun Choe; Wan Beom Park; Ji-Hwan Bang; Eu Suk Kim; Kyoung Un Park; Sang Won Park; Nam-Joong Kim; Myoung-Don Oh; Hong Bin Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

5.  A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Sarah C J Jorgensen; Abdalhamid M Lagnf; Sahil Bhatia; Michael J Rybak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-08       Impact factor: 3.267

6.  Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin.

Authors:  Kerry J Welsh; Kimberly A Skrobarcek; April N Abbott; Cole T Lewis; Mark C Kruzel; Evan M Lewis; Jeanelle M Gardiner; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

7.  Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia.

Authors:  James Price; Gillian Baker; Ian Heath; Karen Walker-Bone; Marc Cubbon; Sally Curtis; Mark C Enright; Jodi Lindsay; John Paul; Martin Llewelyn
Journal:  Int J Microbiol       Date:  2010-03-16

8.  The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Jennifer H Han; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  J Infect       Date:  2012-09-06       Impact factor: 6.072

9.  A comparison of clinical outcomes between healthcare-associated infections due to community-associated methicillin-resistant Staphylococcus aureus strains and healthcare-associated methicillin-resistant S. aureus strains.

Authors:  S J Eells; J A McKinnell; A A Wang; N L Green; D Whang; P O'Hara; M L Brown; L G Miller
Journal:  Epidemiol Infect       Date:  2012-12-06       Impact factor: 2.451

Review 10.  Where does a Staphylococcus aureus vaccine stand?

Authors:  V G Fowler; R A Proctor
Journal:  Clin Microbiol Infect       Date:  2014-05       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.